WORLD PEPTIDEFOUNDATION
← Master Registry

Published peptide research references

Maridebart cafraglutide

Governed registry record

4 approved source records with original-source links. Source verification confirms the reference and its connection to this record; it does not certify every scientific conclusion or establish safety or efficacy.

Approved source records

  1. A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings.

    DOI: 10.1038/s42255-023-00966-w

    Source identity and connection checked by Codex (AI).

  2. Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity.

    DOI: 10.2337/dci24-0003

    Source identity and connection checked by Codex (AI).

  3. Novel GLP-1-based Medications for Type 2 Diabetes and Obesity.

    DOI: 10.1210/endrev/bnaf036

    Source identity and connection checked by Codex (AI).

  4. Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity - A Phase 2 Trial.

    DOI: 10.1056/nejmoa2504214

    Source identity and connection checked by Codex (AI).

Legacy research context

Context from the legacy curated dataset. Its counts describe that dataset and are separate from the live approved source records above.

Researchers represented

  • Jastreboff AM
  • Ryan DH
  • Bays HE
  • Ebeling PR
  • Mackowski MG
  • Philipose N
  • Ross L
  • Liu Y
  • Burns CE
  • Abbasi SA
  • Pannacciulli N
  • MariTide Phase 2 Obesity Trial Investigators
  • Son JW
  • le Roux CW
  • Blüher M
  • Nauck MA
  • Lim S
  • Drucker DJ
  • Véniant MM
  • Lu SC
  • Atangan L
  • Komorowski R
  • Stanislaus S
  • Cheng Y
  • Wu B
  • Falsey JR
  • Hager T
  • Thomas VA
  • Ambhaikar M
  • Sharpsten L
  • Zhu Y
  • Kurra V
  • Jeswani R
  • Oberoi RK
  • Parnes JR
  • Honarpour N
  • Neutel J
  • Strande JL